HC Wainwright Forecasts Sutro Biopharma FY2030 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO) – HC Wainwright issued their FY2030 EPS estimates for shares of Sutro Biopharma in a note issued to investors on Tuesday, March 24th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($4.43) per share for the year. HC Wainwright has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings data on Monday, March 23rd. The company reported ($5.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.66) by ($0.73). The firm had revenue of $11.65 million for the quarter, compared to the consensus estimate of $9.26 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%.

STRO has been the subject of several other research reports. Wedbush reissued a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Citizens Jmp upgraded Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price on the stock in a research note on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. Finally, Wells Fargo & Company raised Sutro Biopharma from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $8.00 to $27.00 in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $34.33.

Sutro Biopharma Stock Performance

Shares of NASDAQ STRO opened at $23.57 on Wednesday. The firm’s 50 day moving average price is $18.39 and its 200-day moving average price is $12.68. Sutro Biopharma has a 52-week low of $5.23 and a 52-week high of $26.54. The company has a market cap of $200.58 million, a PE ratio of -0.90 and a beta of 1.47.

Institutional Investors Weigh In On Sutro Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State of Tennessee Department of Treasury bought a new stake in Sutro Biopharma in the 4th quarter worth approximately $86,000. Jane Street Group LLC purchased a new stake in Sutro Biopharma during the 4th quarter valued at $265,000. Bridgeway Capital Management LLC lifted its holdings in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after buying an additional 30,000 shares during the period. ADAR1 Capital Management LLC bought a new position in shares of Sutro Biopharma during the 4th quarter valued at $776,000. Finally, Spruce Street Capital LP purchased a new position in shares of Sutro Biopharma in the 4th quarter worth $875,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

More Sutro Biopharma News

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Two analyst upgrades with much higher price targets — HC Wainwright moved from Neutral to Buy and set a $28 target; Wells Fargo upgraded to Overweight with a $27 target — signaling renewed broker confidence and providing fresh buy-side impetus. Article Title
• Positive Sentiment: Pipeline progress: company reported dosing three cohorts in the Phase 1 trial of STRO-004 (TF ADC) and remains on track to report initial clinical data in mid‑2026 — a near‑term binary catalyst that can materially re-rate the stock if data are positive. Article Title
• Neutral Sentiment: Revenue beat: Sutro reported revenue of $11.65M versus analyst expectations of $9.26M, showing commercial or partnership receipts stronger than modeled — a positive data point, but offset by large GAAP losses. Press Release
• Neutral Sentiment: Short-interest data released for March shows zero reported short shares (and nonsensical NaN changes/days-to-cover numbers) — this appears to be a reporting/data issue and should not be interpreted as an actual clean short position. No reliable impact indicated.
• Negative Sentiment: Large EPS miss: Sutro reported a (-$5.39) EPS, missing consensus (-$4.66) by $0.73 and showing a very negative net margin and ROE — a reminder of high burn and continued operating losses that keep dilution risk and financing needs on the table. Press Release

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.